Fundz

Aura Biosciences Secures $237.55 Million in Public Offering

PUBLIC · AURAMay 04, 2026

Amount Raised

$238 Million

Round Type

Post-IPO Equity

BostonBiotechnologyHealth CareTherapeutics

Investors

Evercore Group L.L.C.TD Securities (USA) LLCLeerink Partners LLC

Description

On May 4, 2026, Aura Biosciences, Inc. completed an underwritten public offering of common stock. The offering consisted of 39,591,000 shares at an offering price of $6.00 per share. Additionally, pre-funded warrants to purchase up to 3,800,000 shares were also offered

Quick answer

Aura Biosciences, Inc. raised $238 Million in a Post-IPO Equity round, dated May 4, 2026. Investors: Evercore Group L.L.C., TD Securities (USA) LLC and Leerink Partners LLC. Aura Biosciences, Inc. is based in Boston, Massachusetts, United States.

How much did Aura Biosciences, Inc. raise?
Aura Biosciences, Inc. raised $238 Million in a Post-IPO Equity round on May 4, 2026.
Who invested in Aura Biosciences, Inc?
Evercore Group L.L.C., TD Securities (USA) LLC and Leerink Partners LLC are named as investors in this round.
What does Aura Biosciences, Inc. do?
Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications.
Where is Aura Biosciences, Inc. based and how big is it?
Aura Biosciences, Inc. is based in Boston, Massachusetts, United States. Fundz records about 110 employees.
Who are the decision-makers at Aura Biosciences, Inc?
Fundz holds 1 contact at Aura Biosciences, Inc. Names and contact details are shown to Fundz members.

Source: Fundz verified event record.

Who else raised in Therapeutics and Biotechnology around the same time

Companies in the same sectors as Aura Biosciences, Inc. that raised within 45 days of this round, from Fundz verified event records.

  • Vedana raised $46M (Series A) on June 17, 2026.
  • Aplagon raised $5.6M (Funding Round) on June 17, 2026.
  • Racura Oncology raised $34M (Funding Round) on June 17, 2026.
  • Vedana Therapeutics raised $46M (Series A) on June 17, 2026.
  • Emmecell raised an undisclosed amount (Funding Round) on June 16, 2026.
  • SpliSense raised $13M (Funding Round) on June 16, 2026.

Who to call at Aura Biosciences, Inc., and when

A new round usually means Aura Biosciences, Inc. is about to hire and buy. The teams that reach out first get the meeting.

  • An alert the day Aura Biosciences, Inc. raises, hires an executive or expands, scored against what you sell
  • The decision-makers there, with verified emails
  • Who you already know at Aura Biosciences, Inc., from your own LinkedIn network

Works inside ChatGPT and Claude. Ask who to call at Aura Biosciences, Inc.. With Fundz connected, it knows.

Watch Fundz in
See plan options
Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce 4.8/5 on G2

Company Information

Company

Aura Biosciences, Inc.

Location

85 BOLTON STREET

Boston, Massachusetts, United States

About

Aura Biosciences is a clinical-stage biotechnology company developing virus-like drug conjugates (VDC), a novel class of therapies, for the treatment of multiple oncology indications. At Aura, our mission is to deliver meaningful therapeutic benefit to a range of cancer indications with high unmet need in which we believe we can establish a new standard of care. We are driven by our passion and commitment to science and the patients battling cancer who are relying on us to pioneer these new therapies. We are focusing the initial development of our VDC technology platform to treat tumors of high unmet need in ocular and urologic oncology. Belzupacap sarotalocan (bel-sar), our first VDC candidate, is being developed for the first-line treatment of early-stage choroidal melanoma, a rare disease with no drugs approved. Beyond early-stage choroidal melanoma, we are developing bel-sar in additional ocular oncology indications, including choroidal metastasis. Leveraging our VDCs’ broad tumor targeting capabilities, we have also initiated a clinical program in non-muscle invasive bladder cancer, or NMIBC, our first non-ocular solid tumor indication.

AI made execution free. Knowing first is the whole game now.

Fundz sees it the moment Aura Biosciences, Inc. raises, hires an exec or expands, usually minutes after it happens, and tells you who to reach.

Related People

1 contact
Verified contacts58 people are listed at Aura Biosciences, Inc.. We don't have their email yet.See plans and pricing
Predictive Intelligence
Strategic

ML-powered predictions for Aura Biosciences, Inc.'s next move

See what Strategic adds

Aura Biosciences, Inc. raised. Fundz records a round at a median of 3.6 minutes from the SEC filing, with the decision-maker attached.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.

Fundz is a real-time business intelligence platform powered by agentic AI that proactively delivers personalized daily signals, including funding rounds, executive changes, M&A activity, 13F institutional filings, SEC 8-K events, investor activity, and website modifications, based on each user's watchlist and ICP. A trusted data source at firms such as BlackRock, Oracle, Kleiner Perkins, LinkedIn, HubSpot, and Cloudflare, Fundz democratizes the institutional-grade intelligence that previously required a PitchBook or Bloomberg terminal. Features include Daily Briefing for AI-powered daily briefings, and unified cross-signal alerts across 281,000+ organizations. Developers and data teams can access these signals programmatically via the Fundz Funding Data API, with transparent published pricing.